176 related articles for article (PubMed ID: 38179723)
41. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
[TBL] [Abstract][Full Text] [Related]
42. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.
You X; Jiang W; Lu W; Zhang H; Yu T; Tian J; Wen S; Garcia-Manero G; Huang P; Hu Y
Cancer Commun (Lond); 2019 Apr; 39(1):17. PubMed ID: 30947742
[TBL] [Abstract][Full Text] [Related]
43. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
[TBL] [Abstract][Full Text] [Related]
44. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.
Grunwald MR; Tseng LH; Lin MT; Pratz KW; Eshleman JR; Levis MJ; Gocke CD
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1989-95. PubMed ID: 25240816
[TBL] [Abstract][Full Text] [Related]
45. Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis.
Chen S; Chen Y; Zhu Z; Tan H; Lu J; Qin P; Xu L
Int J Med Sci; 2020; 17(9):1269-1280. PubMed ID: 32547322
[No Abstract] [Full Text] [Related]
46. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
[TBL] [Abstract][Full Text] [Related]
47. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
[TBL] [Abstract][Full Text] [Related]
48. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
[TBL] [Abstract][Full Text] [Related]
49. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
50. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
[TBL] [Abstract][Full Text] [Related]
51. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Guenounou S; Delabesse E; Récher C
Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
[TBL] [Abstract][Full Text] [Related]
52. Glutaminolysis is a metabolic dependency in FLT3
Gallipoli P; Giotopoulos G; Tzelepis K; Costa ASH; Vohra S; Medina-Perez P; Basheer F; Marando L; Di Lisio L; Dias JML; Yun H; Sasca D; Horton SJ; Vassiliou G; Frezza C; Huntly BJP
Blood; 2018 Apr; 131(15):1639-1653. PubMed ID: 29463564
[TBL] [Abstract][Full Text] [Related]
53. [FLT3 mutations in children with acute myeloid leukemia: a single center study].
Ruan M; Wang YQ; Zhang L; Liu TF; Liu F; Liu XM; Zhang JY; Zou Y; Chen YM; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):863-6. PubMed ID: 22099191
[TBL] [Abstract][Full Text] [Related]
54. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
55. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
56. IGF2BP2 promotes lncRNA DANCR stability mediated glycolysis and affects the progression of FLT3-ITD + acute myeloid leukemia.
Wu S; Chi C; Weng S; Zhou W; Liu Z
Apoptosis; 2023 Aug; 28(7-8):1035-1047. PubMed ID: 37060505
[TBL] [Abstract][Full Text] [Related]
57. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
58. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
59. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
60. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
